Filtros de búsqueda

Lista de obras de

A Bayesian response-adaptive trial in tuberculosis: The endTB trial.

artículo científico publicado en 2016

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer

artículo científico publicado en 2020

A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly

scientific article published on 27 April 2020

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

scientific article published on 08 May 2018

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases

artículo científico publicado en 2019

Adding experimental arms to platform clinical trials: randomization procedures and interim analyses

artículo científico publicado en 2017

Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

scientific article published on 24 April 2020

Bayesian Adaptive Randomization in Dose-Finding Trials

scientific article published on 07 December 2018

Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma ⬇️

artículo científico publicado el 29 de mayo de 2012

Bayesian response-adaptive designs for basket trials

artículo científico publicado en 2017

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom's Macroglobulinemia patients

artículo científico publicado en 2018

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group

artículo científico publicado en 2014

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma

artículo científico publicado en 2015

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

artículo científico publicado en 2020

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials

artículo científico publicado en 2015

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data

artículo científico publicado en 2019

Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer

artículo científico publicado en 2017

Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications

artículo científico publicado en 2019

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial

artículo científico publicado en 2020

Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data

scientific article published on 25 June 2018

Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations

artículo científico publicado en 2017

Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes

artículo científico publicado en 2022

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

scientific article published on 22 May 2020

Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma

artículo científico publicado en 2015

Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy

artículo científico publicado en 2018

INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials

scientific article published on 15 November 2019

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma

scientific article published on 27 March 2019

Keynote 48: Is it really for everyone?

scientific article published on 04 May 2020

Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs

artículo científico publicado en 2019

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

artículo científico publicado en 2017

Multi-study Factor Analysis

artículo científico publicado en 2019

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center

scientific article published on 16 September 2020

Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers

artículo científico publicado en 2015

Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis

scientific article published on 11 February 2020

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

artículo científico publicado en 2019

Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide

artículo científico publicado en 2020

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study

Prognostic role of circulating exosomal miRNAs in multiple myeloma

artículo científico publicado en 2017

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia

artículo científico publicado en 2019

Progression-free survival: too much risk, not enough reward?

artículo científico publicado en 2014

Reply to "Keynote 48: Is it really for everyone?"

artículo científico publicado en 2020

Reply to B. Freidlin et al ⬇️

artículo científico publicado el 1 de marzo de 2013

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial

artículo científico publicado en 2019

Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer

scientific article published on 13 March 2020

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

artículo científico publicado en 2018

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs

artículo científico publicado en 2019

Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.

scientific article published in 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda